First Time Loading...

Agenus Inc
NASDAQ:AGEN

Watchlist Manager
Agenus Inc Logo
Agenus Inc
NASDAQ:AGEN
Watchlist
Price: 5.64 USD 13.48%
Updated: Apr 19, 2024

Intrinsic Value

AGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. [ Read More ]

The intrinsic value of one AGEN stock under the Base Case scenario is 3.11 USD. Compared to the current market price of 5.64 USD, Agenus Inc is Overvalued by 45%.

Key Points:
AGEN Intrinsic Value
Base Case
3.11 USD
Overvaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Agenus Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Agenus Inc

Provide an overview of the primary business activities
of Agenus Inc.

What unique competitive advantages
does Agenus Inc hold over its rivals?

What risks and challenges
does Agenus Inc face in the near future?

Has there been any significant insider trading activity
in Agenus Inc recently?

Summarize the latest earnings call
of Agenus Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Agenus Inc.

Provide P/S
for Agenus Inc.

Provide P/E
for Agenus Inc.

Provide P/OCF
for Agenus Inc.

Provide P/FCFE
for Agenus Inc.

Provide P/B
for Agenus Inc.

Provide EV/S
for Agenus Inc.

Provide EV/GP
for Agenus Inc.

Provide EV/EBITDA
for Agenus Inc.

Provide EV/EBIT
for Agenus Inc.

Provide EV/OCF
for Agenus Inc.

Provide EV/FCFF
for Agenus Inc.

Provide EV/IC
for Agenus Inc.

Show me price targets
for Agenus Inc made by professional analysts.

What are the Revenue projections
for Agenus Inc?

How accurate were the past Revenue estimates
for Agenus Inc?

What are the Net Income projections
for Agenus Inc?

How accurate were the past Net Income estimates
for Agenus Inc?

What are the EPS projections
for Agenus Inc?

How accurate were the past EPS estimates
for Agenus Inc?

What are the EBIT projections
for Agenus Inc?

How accurate were the past EBIT estimates
for Agenus Inc?

Compare the revenue forecasts
for Agenus Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Agenus Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Agenus Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Agenus Inc compared to its peers.

Compare the P/E ratios
of Agenus Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Agenus Inc with its peers.

Analyze the financial leverage
of Agenus Inc compared to its main competitors.

Show all profitability ratios
for Agenus Inc.

Provide ROE
for Agenus Inc.

Provide ROA
for Agenus Inc.

Provide ROIC
for Agenus Inc.

Provide ROCE
for Agenus Inc.

Provide Gross Margin
for Agenus Inc.

Provide Operating Margin
for Agenus Inc.

Provide Net Margin
for Agenus Inc.

Provide FCF Margin
for Agenus Inc.

Show all solvency ratios
for Agenus Inc.

Provide D/E Ratio
for Agenus Inc.

Provide D/A Ratio
for Agenus Inc.

Provide Interest Coverage Ratio
for Agenus Inc.

Provide Altman Z-Score Ratio
for Agenus Inc.

Provide Quick Ratio
for Agenus Inc.

Provide Current Ratio
for Agenus Inc.

Provide Cash Ratio
for Agenus Inc.

What is the historical Revenue growth
over the last 5 years for Agenus Inc?

What is the historical Net Income growth
over the last 5 years for Agenus Inc?

What is the current Free Cash Flow
of Agenus Inc?

Financials

Balance Sheet Decomposition
Agenus Inc

Current Assets 112.4m
Cash & Short-Term Investments 76.1m
Receivables 25.8m
Other Current Assets 10.5m
Non-Current Assets 201.5m
PP&E 163m
Intangibles 29.1m
Other Non-Current Assets 9.3m
Current Liabilities 255.9m
Accounts Payable 61.4m
Accrued Liabilities 47.9m
Other Current Liabilities 146.6m
Non-Current Liabilities 218.3m
Long-Term Debt 12.8m
Other Non-Current Liabilities 205.6m
Efficiency

Earnings Waterfall
Agenus Inc

Revenue
156.3m USD
Cost of Revenue
-3.1m USD
Gross Profit
153.2m USD
Operating Expenses
-313.3m USD
Operating Income
-160.1m USD
Other Expenses
-85.9m USD
Net Income
-246m USD

Free Cash Flow Analysis
Agenus Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AGEN Profitability Score
Profitability Due Diligence

Agenus Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
ROE is Increasing
52/100
Profitability
Score

Agenus Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

AGEN Solvency Score
Solvency Due Diligence

Agenus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
36/100
Solvency
Score

Agenus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGEN Price Targets Summary
Agenus Inc

Wall Street analysts forecast AGEN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGEN is 5.61 USD with a low forecast of 3.03 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.03 USD
46% Downside
Average
Price Target
5.61 USD
1% Downside
Highest
Price Target
8.4 USD
49% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AGEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AGEN Price
Agenus Inc

1M 1M
+902%
6M 6M
+488%
1Y 1Y
+219%
3Y 3Y
+125%
5Y 5Y
+127%
10Y 10Y
+124%
Annual Price Range
5.64
52w Low
0.5059
52w High
10.074
Price Metrics
Average Annual Return 3.87%
Standard Deviation of Annual Returns 40.13%
Max Drawdown -92%
Shares Statistics
Market Capitalization 2.2B USD
Shares Outstanding 418 920 000
Percentage of Shares Shorted 11.48%

AGEN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Agenus Inc Logo
Agenus Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.2B USD

Dividend Yield

0%

Description

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

Contact

MASSACHUSETTS
Lexington
3 Forbes Rd
+17816744400.0
http://agenusbio.com/

IPO

2000-02-04

Employees

441

Officers

Founder, Executive Chairman & CEO
Dr. Garo H. Armen Ph.D.
VP of Finance, Principal Financial Officer & Principal Accounting Officer
Ms. Christine M. Klaskin
Chief Medical Officer
Dr. Steven J. O'Day M.D., Ph.D.
Chief Information Officer
Craig Winter
Head of Investor Relations
Mr. Zack Armen
Chief People Officer
Ms. Tracy Mazza Clemente
Show More
Scientific Director & Head of Drug Discovery
Mr. Dhan Chand
Chief Manufacturing Officer
Mr. Alfred Dadson
Chief Quality Officer
Mr. Eric Humes
Member of Advisory Board & Chief Strategic Advisor
Dr. Todd Jude Yancey M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AGEN stock?

The intrinsic value of one AGEN stock under the Base Case scenario is 3.11 USD.

Is AGEN stock undervalued or overvalued?

Compared to the current market price of 5.64 USD, Agenus Inc is Overvalued by 45%.